|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:administeredBy
|
gptkb:physician
self-administration (with training)
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:atopic_dermatitis
2017
asthma
chronic rhinosinusitis with nasal polyposis
eosinophilic esophagitis
|
|
gptkbp:ATCCode
|
gptkb:D11AH05
|
|
gptkbp:brand
|
gptkb:Dupixent
|
|
gptkbp:contraindication
|
hypersensitivity to dupilumab
|
|
gptkbp:cost
|
high (varies by country and insurance)
|
|
gptkbp:developedBy
|
gptkb:Sanofi
gptkb:Regeneron_Pharmaceuticals
|
|
gptkbp:form
|
pre-filled pen
pre-filled syringe
|
|
gptkbp:genericName
|
gptkb:dupilumab
|
|
gptkbp:halfLife
|
~14-16 days
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Dupixent
|
|
gptkbp:indication
|
gptkb:prurigo_nodularis
chronic rhinosinusitis with nasal polyposis
eosinophilic esophagitis
moderate-to-severe asthma
moderate-to-severe atopic dermatitis
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:macromoleculeType
|
gptkb:monoclonal_antibody
|
|
gptkbp:marketedIn
|
gptkb:Australia
gptkb:Canada
gptkb:European_Union
gptkb:Japan
gptkb:United_States
|
|
gptkbp:mechanismOfAction
|
IL-4 receptor alpha antagonist
|
|
gptkbp:patent
|
gptkb:Sanofi
gptkb:Regeneron_Pharmaceuticals
|
|
gptkbp:pregnancyCategory
|
N/A (consult physician)
|
|
gptkbp:prescribes
|
adolescents
adults
children (age restrictions apply)
|
|
gptkbp:prescriptionRequired
|
yes
|
|
gptkbp:routeOfAdministration
|
subcutaneous injection
|
|
gptkbp:sideEffect
|
conjunctivitis
injection site reactions
eye inflammation
oral herpes
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:target
|
gptkb:interleukin-4
gptkb:interleukin-13
|
|
gptkbp:bfsParent
|
gptkb:Sanofi
|
|
gptkbp:bfsLayer
|
5
|